Vir Biotechnology, Inc.

NASDAQ:VIR

Biotechnology

Healthcare
$9.15 -2.63%

-$0.25 today

Market cap
$1.57B
Beta
1.64
P/E (TTM)
-3.0
EPS (TTM)
-$3.00
52W Low $4.16High $11.66

Volume 2.15M

Average 1.76M

VIR Total Debt

Short-term and long-term borrowings combined.

Vir Biotechnology, Inc.NASDAQ: VIR

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt broadly unchanged from a year ago

Total debt stood at $95.58M at the end of Q1 FY2026, down 0.5% from a year earlier and down 48.9% from the prior quarter. Over 3 fiscal years it compounded at +13.5% a year.

Context

  • Total debt amounted to 9.3% of total assets at the end of Q1 FY2026, up 2.0 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -0.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$95.58M-48.9% QoQ
Last fiscal yearDec 2025
$186.91M+90.9% YoY
Year agoMar 2025
$96.1M-0.5% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.5%——
1 year+90.9%——
3-year CAGR+13.5%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
186.91M USD
Year-over-year change
+90.9%
4-year CAGR
+8.0%

Total Debt vs competitors

How VIR compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -0.5% is the 4th highest of 10, against a peer median of -13.7%.
  • Total debt amounts to 9.3% of total assets for VIR, versus a peer median of 28.3%.
VIR Competitors
Total Debt for VIR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MRNAModerna, Inc.Sep 2026$4.18B USD+199.8%+16.9%31.0%
BCRXBioCryst Pharmaceuticals, Inc.Jun 2026$409.86M USD-41.7%-16.0%73.5%
BNTXBioNTech SEJun 2026€315.97M EUR+17.2%+8.0%1.6%
NVAXNovavax, Inc.Mar 2026$295.06M USD+29.0%-23.2%28.3%
VALNValneva SEMar 2026€209.72M EUR-0.7%+10.8%56.3%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$186.62M USD-13.7%+96.0%59.3%
VIRVir Biotechnology, Inc.Mar 2026$95.58M USD-0.5%+13.5%9.3%
ASMBAssembly Biosciences, Inc.Mar 2026$2.49M USD-17.5%-8.8%1.1%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$634K USD-56.1%-35.4%0.2%
ABUSArbutus Biopharma CorporationMar 2026$631K USD-88.7%-30.6%0.2%
Peer median (excluding VIR) —-13.7%-8.8%28.3%

Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents347.82M848.63M241.58M222.95M234.11M
Short-term Investments360.33M1.55B1.28B682.4M228.75M
Net Receivables773.08M0003.6M
Inventory00000
Other Current Assets8.59M59.2M65.82M137.11M47.62M
Total Current Assets1.56B2.52B1.59B1.04B514.08M
Property, Plant & Equipment (Net)130.05M188.17M167.2M122.86M117.72M
Goodwill16.94M16.94M16.94M16.94M16.94M
Intangible Assets33.29M32.76M22.57M8.1M7.85M
Long-term Investments201.39M23.93M105.28M190.02M314.58M
Tax Assets0249.72M000
Other Non-current Assets9.78M(228.5M)18.86M18.42M31.66M
Total Non-current Assets391.45M283.01M330.83M356.33M488.74M
Total Assets1.95B2.8B1.92B1.4B1B
Account Payables6.52M6.42M6.33M5.08M9.8M
Short-term Debt00008.8M
Tax Payables6.22M15.23M149K00
Deferred Revenue98.21M15.52M64.85M12.65M0
Other Current Liabilities07.65M9.35M16.06M74.21M
Total Current Liabilities341.24M511.03M175.41M119.66M92.82M
Long-term Debt000089.05M
Deferred Tax Liabilities18.44M3.25M000
Deferred Revenue (Non-current)3.82M53.21M1.53M00
Other Non-current Liabilities25.36M32.8M40.22M38.63M(33.38M)
Total Non-current Liabilities181.18M213.1M153.42M128.77M144.73M
Total Liabilities522.42M724.13M328.82M248.43M237.55M
Common Stock13K13K13K14K14K
Retained Earnings(138.6M)377.24M(237.82M)(759.78M)(1.2B)
Accumulated OCI(1.1M)(9.12M)(815K)(1.72M)(2.06M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.43B2.08B1.59B1.15B765.28M
Total Debt137.49M127.97M124.54M97.89M186.91M
Net Debt(210.33M)(720.66M)(117.04M)(125.06M)(47.2M)

Vir Biotechnology, Inc.

NASDAQ:VIR

Intrinsic Alpha fair value

Locked

Current Price

$9.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.